Tuberculosis and other opportunistic infections in tofacitinib-treated patients with rheumatoid arthritis

ObjectivesTo evaluate the risk of opportunistic infections (OIs) in patients with rheumatoid arthritis (RA) treated with tofacitinib.MethodsPhase II, III and long-term extension clinical trial data (April 2013 data-cut) from the tofacitinib RA programme were reviewed. OIs defined a priori included m...

Full description

Saved in:
Bibliographic Details
Published inAnnals of the rheumatic diseases Vol. 75; no. 6; pp. 1133 - 1138
Main Authors Winthrop, K L, Park, S-H, Gul, A, Cardiel, M H, Gomez-Reino, J J, Tanaka, Y, Kwok, K, Lukic, T, Mortensen, E, Ponce de Leon, D, Riese, R, Valdez, H
Format Journal Article
LanguageEnglish
Published England Elsevier Limited 01.06.2016
BMJ Publishing Group
SeriesExtended report
Subjects
Antirheumatic Agents - adverse effects
Antirheumatic Agents - therapeutic use
Arthritis, Rheumatoid - drug therapy
Arthritis, Rheumatoid - epidemiology
Arthritis, Rheumatoid - immunology
Clinical and Epidemiological Research
Clinical Trials as Topic
Cytomegalovirus
Herpes viruses
Humans
Immunocompromised Host
Immunosuppressive Agents - adverse effects
Immunosuppressive Agents - therapeutic use
Incidence
Infections
Janus Kinase 3 - antagonists & inhibitors
Kinases
Opportunistic Infections - chemically induced
Opportunistic Infections - epidemiology
Opportunistic Infections - immunology
Patients
Piperidines - adverse effects
Piperidines - therapeutic use
Pneumonia
Protein Kinase Inhibitors - adverse effects
Protein Kinase Inhibitors - therapeutic use
Pyrimidines - adverse effects
Pyrimidines - therapeutic use
Pyrroles - adverse effects
Pyrroles - therapeutic use
Regions
Rheumatoid arthritis
Risk Assessment
Steroids
Tuberculosis
Tuberculosis - chemically induced
Tuberculosis - epidemiology
Tuberculosis - immunology
Tumor necrosis factor-TNF
Viral infections
United States > US
Japan
DMARDs (synthetic)
Infections
Treatment
Tuberculosis
Rheumatoid Arthritis
Online AccessGet full text

Cover

Abstract ObjectivesTo evaluate the risk of opportunistic infections (OIs) in patients with rheumatoid arthritis (RA) treated with tofacitinib.MethodsPhase II, III and long-term extension clinical trial data (April 2013 data-cut) from the tofacitinib RA programme were reviewed. OIs defined a priori included mycobacterial and fungal infections, multidermatomal herpes zoster and other viral infections associated with immunosuppression. For OIs, we calculated crude incidence rates (IRs; per 100 patient-years (95% CI)); for tuberculosis (TB) specifically, we calculated rates stratified by patient enrolment region according to background TB IR (per 100 patient-years): low (≤0.01), medium (>0.01 to ≤0.05) and high (>0.05).ResultsWe identified 60 OIs among 5671 subjects; all occurred among tofacitinib-treated patients. TB (crude IR 0.21, 95% CI of (0.14 to 0.30)) was the most common OI (n=26); median time between drug start and diagnosis was 64 weeks (range 15–161 weeks). Twenty-one cases (81%) occurred in countries with high background TB IR, and the rate varied with regional background TB IR: low 0.02 (0.003 to 0.15), medium 0.08 (0.03 to 0.21) and high 0.75 (0.49 to 1.15). In Phase III studies, 263 patients diagnosed with latent TB infection were treated with isoniazid and tofacitinib concurrently; none developed TB. For OIs other than TB, 34 events were reported (crude IR 0.25 (95% CI 0.18 to 0.36)).ConclusionsWithin the global tofacitinib RA development programme, TB was the most common OI reported but was rare in regions of low and medium TB incidence. Patients who screen positive for latent TB can be treated with isoniazid during tofacitinib therapy.
AbstractList Objectives To evaluate the risk of opportunistic infections (OIs) in patients with rheumatoid arthritis (RA) treated with tofacitinib. Methods Phase II, III and long-term extension clinical trial data (April 2013 data-cut) from the tofacitinib RA programme were reviewed. OIs defined a priori included mycobacterial and fungal infections, multidermatomal herpes zoster and other viral infections associated with immunosuppression. For OIs, we calculated crude incidence rates (IRs; per 100 patient-years (95% CI)); for tuberculosis (TB) specifically, we calculated rates stratified by patient enrolment region according to background TB IR (per 100 patient-years): low (â[per thousand]¤0.01), medium (>0.01 to â[per thousand]¤0.05) and high (>0.05). Results We identified 60 OIs among 5671 subjects; all occurred among tofacitinib-treated patients. TB (crude IR 0.21, 95% CI of (0.14 to 0.30)) was the most common OI (n=26); median time between drug start and diagnosis was 64 weeks (range 15-161 weeks). Twenty-one cases (81%) occurred in countries with high background TB IR, and the rate varied with regional background TB IR: low 0.02 (0.003 to 0.15), medium 0.08 (0.03 to 0.21) and high 0.75 (0.49 to 1.15). In Phase III studies, 263 patients diagnosed with latent TB infection were treated with isoniazid and tofacitinib concurrently; none developed TB. For OIs other than TB, 34 events were reported (crude IR 0.25 (95% CI 0.18 to 0.36)). Conclusions Within the global tofacitinib RA development programme, TB was the most common OI reported but was rare in regions of low and medium TB incidence. Patients who screen positive for latent TB can be treated with isoniazid during tofacitinib therapy.
To evaluate the risk of opportunistic infections (OIs) in patients with rheumatoid arthritis (RA) treated with tofacitinib.OBJECTIVESTo evaluate the risk of opportunistic infections (OIs) in patients with rheumatoid arthritis (RA) treated with tofacitinib.Phase II, III and long-term extension clinical trial data (April 2013 data-cut) from the tofacitinib RA programme were reviewed. OIs defined a priori included mycobacterial and fungal infections, multidermatomal herpes zoster and other viral infections associated with immunosuppression. For OIs, we calculated crude incidence rates (IRs; per 100 patient-years (95% CI)); for tuberculosis (TB) specifically, we calculated rates stratified by patient enrolment region according to background TB IR (per 100 patient-years): low (≤0.01), medium (>0.01 to ≤0.05) and high (>0.05).METHODSPhase II, III and long-term extension clinical trial data (April 2013 data-cut) from the tofacitinib RA programme were reviewed. OIs defined a priori included mycobacterial and fungal infections, multidermatomal herpes zoster and other viral infections associated with immunosuppression. For OIs, we calculated crude incidence rates (IRs; per 100 patient-years (95% CI)); for tuberculosis (TB) specifically, we calculated rates stratified by patient enrolment region according to background TB IR (per 100 patient-years): low (≤0.01), medium (>0.01 to ≤0.05) and high (>0.05).We identified 60 OIs among 5671 subjects; all occurred among tofacitinib-treated patients. TB (crude IR 0.21, 95% CI of (0.14 to 0.30)) was the most common OI (n=26); median time between drug start and diagnosis was 64 weeks (range 15-161 weeks). Twenty-one cases (81%) occurred in countries with high background TB IR, and the rate varied with regional background TB IR: low 0.02 (0.003 to 0.15), medium 0.08 (0.03 to 0.21) and high 0.75 (0.49 to 1.15). In Phase III studies, 263 patients diagnosed with latent TB infection were treated with isoniazid and tofacitinib concurrently; none developed TB. For OIs other than TB, 34 events were reported (crude IR 0.25 (95% CI 0.18 to 0.36)).RESULTSWe identified 60 OIs among 5671 subjects; all occurred among tofacitinib-treated patients. TB (crude IR 0.21, 95% CI of (0.14 to 0.30)) was the most common OI (n=26); median time between drug start and diagnosis was 64 weeks (range 15-161 weeks). Twenty-one cases (81%) occurred in countries with high background TB IR, and the rate varied with regional background TB IR: low 0.02 (0.003 to 0.15), medium 0.08 (0.03 to 0.21) and high 0.75 (0.49 to 1.15). In Phase III studies, 263 patients diagnosed with latent TB infection were treated with isoniazid and tofacitinib concurrently; none developed TB. For OIs other than TB, 34 events were reported (crude IR 0.25 (95% CI 0.18 to 0.36)).Within the global tofacitinib RA development programme, TB was the most common OI reported but was rare in regions of low and medium TB incidence. Patients who screen positive for latent TB can be treated with isoniazid during tofacitinib therapy.CONCLUSIONSWithin the global tofacitinib RA development programme, TB was the most common OI reported but was rare in regions of low and medium TB incidence. Patients who screen positive for latent TB can be treated with isoniazid during tofacitinib therapy.
ObjectivesTo evaluate the risk of opportunistic infections (OIs) in patients with rheumatoid arthritis (RA) treated with tofacitinib.MethodsPhase II, III and long-term extension clinical trial data (April 2013 data-cut) from the tofacitinib RA programme were reviewed. OIs defined a priori included mycobacterial and fungal infections, multidermatomal herpes zoster and other viral infections associated with immunosuppression. For OIs, we calculated crude incidence rates (IRs; per 100 patient-years (95% CI)); for tuberculosis (TB) specifically, we calculated rates stratified by patient enrolment region according to background TB IR (per 100 patient-years): low (≤0.01), medium (>0.01 to ≤0.05) and high (>0.05).ResultsWe identified 60 OIs among 5671 subjects; all occurred among tofacitinib-treated patients. TB (crude IR 0.21, 95% CI of (0.14 to 0.30)) was the most common OI (n=26); median time between drug start and diagnosis was 64 weeks (range 15–161 weeks). Twenty-one cases (81%) occurred in countries with high background TB IR, and the rate varied with regional background TB IR: low 0.02 (0.003 to 0.15), medium 0.08 (0.03 to 0.21) and high 0.75 (0.49 to 1.15). In Phase III studies, 263 patients diagnosed with latent TB infection were treated with isoniazid and tofacitinib concurrently; none developed TB. For OIs other than TB, 34 events were reported (crude IR 0.25 (95% CI 0.18 to 0.36)).ConclusionsWithin the global tofacitinib RA development programme, TB was the most common OI reported but was rare in regions of low and medium TB incidence. Patients who screen positive for latent TB can be treated with isoniazid during tofacitinib therapy.
To evaluate the risk of opportunistic infections (OIs) in patients with rheumatoid arthritis (RA) treated with tofacitinib. Phase II, III and long-term extension clinical trial data (April 2013 data-cut) from the tofacitinib RA programme were reviewed. OIs defined a priori included mycobacterial and fungal infections, multidermatomal herpes zoster and other viral infections associated with immunosuppression. For OIs, we calculated crude incidence rates (IRs; per 100 patient-years (95% CI)); for tuberculosis (TB) specifically, we calculated rates stratified by patient enrolment region according to background TB IR (per 100 patient-years): low (≤0.01), medium (>0.01 to ≤0.05) and high (>0.05). We identified 60 OIs among 5671 subjects; all occurred among tofacitinib-treated patients. TB (crude IR 0.21, 95% CI of (0.14 to 0.30)) was the most common OI (n=26); median time between drug start and diagnosis was 64 weeks (range 15-161 weeks). Twenty-one cases (81%) occurred in countries with high background TB IR, and the rate varied with regional background TB IR: low 0.02 (0.003 to 0.15), medium 0.08 (0.03 to 0.21) and high 0.75 (0.49 to 1.15). In Phase III studies, 263 patients diagnosed with latent TB infection were treated with isoniazid and tofacitinib concurrently; none developed TB. For OIs other than TB, 34 events were reported (crude IR 0.25 (95% CI 0.18 to 0.36)). Within the global tofacitinib RA development programme, TB was the most common OI reported but was rare in regions of low and medium TB incidence. Patients who screen positive for latent TB can be treated with isoniazid during tofacitinib therapy.
Author Mortensen, E
Valdez, H
Winthrop, K L
Gomez-Reino, J J
Gul, A
Tanaka, Y
Riese, R
Lukic, T
Cardiel, M H
Ponce de Leon, D
Park, S-H
Kwok, K
AuthorAffiliation 3 Istanbul Faculty of Medicine , Istanbul University , Istanbul , Turkey
5 Hospital Clínico Universitario de Santiago , Santiago de Compostela , Spain
7 Pfizer Inc , New York, New York , USA
2 Division of Rheumatology, Department of Internal Medicine , Seoul St. Mary's Hospital, The Catholic University of Korea , Seoul , South Korea
6 University of Occupational and Environmental Health , Kitakyushu , Japan
9 Pfizer Inc , Lima , Peru
4 Centro de Investigación Clínica de Morelia SC , Morelia , Mexico
1 Oregon Health and Science University , Portland, Oregon , USA
8 Pfizer Inc , Collegeville , Pennsylvania, USA
10 Pfizer Inc , Groton , Connecticut, USA
AuthorAffiliation_xml – name: 5 Hospital Clínico Universitario de Santiago , Santiago de Compostela , Spain
– name: 2 Division of Rheumatology, Department of Internal Medicine , Seoul St. Mary's Hospital, The Catholic University of Korea , Seoul , South Korea
– name: 9 Pfizer Inc , Lima , Peru
– name: 3 Istanbul Faculty of Medicine , Istanbul University , Istanbul , Turkey
– name: 7 Pfizer Inc , New York, New York , USA
– name: 6 University of Occupational and Environmental Health , Kitakyushu , Japan
– name: 4 Centro de Investigación Clínica de Morelia SC , Morelia , Mexico
– name: 8 Pfizer Inc , Collegeville , Pennsylvania, USA
– name: 1 Oregon Health and Science University , Portland, Oregon , USA
– name: 10 Pfizer Inc , Groton , Connecticut, USA
Author_xml – sequence: 1
  givenname: K L
  surname: Winthrop
  fullname: Winthrop, K L
  email: Winthrop@ohsu.edu
  organization: Oregon Health and Science University, Portland, Oregon, USA
– sequence: 2
  givenname: S-H
  surname: Park
  fullname: Park, S-H
  email: Winthrop@ohsu.edu
  organization: Division of Rheumatology, Department of Internal Medicine, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, South Korea
– sequence: 3
  givenname: A
  surname: Gul
  fullname: Gul, A
  email: Winthrop@ohsu.edu
  organization: Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey
– sequence: 4
  givenname: M H
  orcidid: 0000-0002-2731-9180
  surname: Cardiel
  fullname: Cardiel, M H
  email: Winthrop@ohsu.edu
  organization: Centro de Investigación Clínica de Morelia SC, Morelia, Mexico
– sequence: 5
  givenname: J J
  surname: Gomez-Reino
  fullname: Gomez-Reino, J J
  email: Winthrop@ohsu.edu
  organization: Hospital Clínico Universitario de Santiago, Santiago de Compostela, Spain
– sequence: 6
  givenname: Y
  surname: Tanaka
  fullname: Tanaka, Y
  email: Winthrop@ohsu.edu
  organization: University of Occupational and Environmental Health, Kitakyushu, Japan
– sequence: 7
  givenname: K
  surname: Kwok
  fullname: Kwok, K
  email: Winthrop@ohsu.edu
  organization: Pfizer Inc, New York, New York, USA
– sequence: 8
  givenname: T
  surname: Lukic
  fullname: Lukic, T
  email: Winthrop@ohsu.edu
  organization: Pfizer Inc, New York, New York, USA
– sequence: 9
  givenname: E
  surname: Mortensen
  fullname: Mortensen, E
  email: Winthrop@ohsu.edu
  organization: Pfizer Inc, Collegeville, Pennsylvania, USA
– sequence: 10
  givenname: D
  surname: Ponce de Leon
  fullname: Ponce de Leon, D
  email: Winthrop@ohsu.edu
  organization: Pfizer Inc, Lima, Peru
– sequence: 11
  givenname: R
  surname: Riese
  fullname: Riese, R
  email: Winthrop@ohsu.edu
  organization: Pfizer Inc, Groton, Connecticut, USA
– sequence: 12
  givenname: H
  surname: Valdez
  fullname: Valdez, H
  email: Winthrop@ohsu.edu
  organization: Pfizer Inc, New York, New York, USA
BackLink https://www.ncbi.nlm.nih.gov/pubmed/26318385$$D View this record in MEDLINE/PubMed
BookMark eNqNUU2P1SAUJWaM8-bpX1ASN26qfLRAF5qYiV_JJG7GNQF6a3lpoQLV-O_l-cbJOKtJCNwbzjmcy7lAZyEGQOgFJa8p5eKNCSFNsC2Dzw0jtKub5LR_hHa0Fap2gpyhHSGEN20v5Dm6yPlQW6KoeoLOmeBUcdXtkL_eLCS3zTH7jE0YcCwTJBzXNaayBZ-Ld9iHEVzxMeRa4hJH43zxwdumJDAFBrya4iGUjH_5MuG_3kyJfsAmlSlVcH6KHo9mzvDs5tyjbx8_XF9-bq6-fvpy-f6qsa1SpaEw9EzazgnLWC16xlsBIIiyUnDZK0EVKOcM6xgdRibrkgYG3lk6EtPxPXp30l03u8DgqqtkZr0mv5j0W0fj9f83wU_6e_ypW9Vz0vMq8OpGIMUfG-SiF58dzLMJELesqVSq45LUT9yjl_egh7ilUMerqJ4roqQ6op7fdXRr5V8KFSBPAJdizgnGWwgl-pi3vpO3PuatT3lX5tt7zBqMOSZVR_PzA_jsxLfL4cGP_gG2hsnD
CODEN ARDIAO
CitedBy_id crossref_primary_10_1136_annrheumdis_2016_210322
crossref_primary_10_1080_14740338_2020_1774550
crossref_primary_10_1186_s13075_020_02399_2
crossref_primary_10_1016_j_annonc_2023_08_013
crossref_primary_10_1007_s10787_020_00757_9
crossref_primary_10_1128_CMR_00035_19
crossref_primary_10_1515_revneuro_2018_0027
crossref_primary_10_3390_biomedicines10020228
crossref_primary_10_1038_s41598_017_07261_1
crossref_primary_10_1093_rap_rkac032
crossref_primary_10_2217_imt_2018_0015
crossref_primary_10_1093_ofid_ofw205
crossref_primary_10_3389_fmed_2022_961027
crossref_primary_10_1016_j_abd_2023_03_001
crossref_primary_10_1111_ijd_17501
crossref_primary_10_3899_jrheum_200730
crossref_primary_10_1002_acr_22984
crossref_primary_10_1186_s12865_017_0225_9
crossref_primary_10_1016_j_idcr_2020_e00892
crossref_primary_10_1080_14656566_2016_1241237
crossref_primary_10_1080_1744666X_2019_1705785
crossref_primary_10_1080_17512433_2023_2285011
crossref_primary_10_1097_CM9_0000000000001948
crossref_primary_10_3390_ijms25179184
crossref_primary_10_1016_j_idc_2020_02_006
crossref_primary_10_1016_j_jbspin_2023_105568
crossref_primary_10_1016_j_monrhu_2022_07_004
crossref_primary_10_3390_jcm13010015
crossref_primary_10_1097_MCG_0000000000001823
crossref_primary_10_1016_j_rcreu_2018_08_002
crossref_primary_10_1111_1756_185X_13853
crossref_primary_10_1080_17474124_2022_2106216
crossref_primary_10_1136_annrheumdis_2020_217092
crossref_primary_10_1111_jdv_18263
crossref_primary_10_1016_j_revmed_2024_12_007
crossref_primary_10_3389_fimmu_2020_591176
crossref_primary_10_1093_ecco_jcc_jjx003
crossref_primary_10_1093_rheumatology_kez681
crossref_primary_10_1093_mmy_myy136
crossref_primary_10_3390_jcm12196419
crossref_primary_10_1136_annrheumdis_2016_210708
crossref_primary_10_1007_s40265_020_01349_1
crossref_primary_10_1016_j_rcreue_2018_08_002
crossref_primary_10_1136_rmdopen_2021_001595
crossref_primary_10_1111_jdv_15937
crossref_primary_10_1136_annrheumdis_2014_207178
crossref_primary_10_1371_journal_pone_0178035
crossref_primary_10_1007_s12664_024_01524_2
crossref_primary_10_1177_17562848231179871
crossref_primary_10_47360_1995_4484_2023_16_24
crossref_primary_10_2174_1381612825666190321104424
crossref_primary_10_1136_annrheumdis_2019_216852
crossref_primary_10_2340_actadv_v102_2075
crossref_primary_10_1093_ecco_jcc_jjab052
crossref_primary_10_1111_1756_185X_14570
crossref_primary_10_1016_j_jorep_2023_100196
crossref_primary_10_1093_mrcr_rxac098
crossref_primary_10_1111_jgh_15256
crossref_primary_10_1371_journal_pone_0306548
crossref_primary_10_1007_s40264_020_00904_9
crossref_primary_10_1016_j_monrhu_2017_10_001
crossref_primary_10_1080_1744666X_2022_2014323
crossref_primary_10_1097_MD_0000000000011609
crossref_primary_10_1111_jdv_15489
crossref_primary_10_1136_annrheumdis_2021_220651
crossref_primary_10_1002_art_40803
crossref_primary_10_1111_1756_185X_13513
crossref_primary_10_1053_j_gastro_2020_08_064
crossref_primary_10_1016_j_intimp_2020_106731
crossref_primary_10_3899_jrheum_171361
crossref_primary_10_1007_s40265_020_01293_0
crossref_primary_10_1080_14656566_2017_1409205
crossref_primary_10_1093_ecco_jcc_jjaa017
crossref_primary_10_1159_000531701
crossref_primary_10_12688_f1000research_11327_1
crossref_primary_10_1111_joim_20064
crossref_primary_10_1016_j_dld_2023_10_008
crossref_primary_10_1038_nrrheum_2017_23
crossref_primary_10_3390_v13122379
crossref_primary_10_1002_iub_2413
crossref_primary_10_1007_s00393_022_01274_6
crossref_primary_10_1016_j_cmi_2024_04_011
crossref_primary_10_1093_ibd_izy150
crossref_primary_10_1007_s10238_021_00751_7
crossref_primary_10_1016_j_gastre_2020_04_006
crossref_primary_10_1136_bmjopen_2019_030999
crossref_primary_10_7759_cureus_79456
crossref_primary_10_1007_s40744_024_00677_y
crossref_primary_10_1016_j_autrev_2019_102390
crossref_primary_10_2217_imt_2015_0031
crossref_primary_10_1016_j_jbspin_2019_09_005
crossref_primary_10_1177_2050640620935732
crossref_primary_10_4103_ijt_ijt_28_21
crossref_primary_10_1016_j_ejca_2021_09_037
crossref_primary_10_1097_RHU_0000000000000786
crossref_primary_10_1007_s41970_017_0001_6
crossref_primary_10_1016_j_rhum_2020_01_032
crossref_primary_10_1007_s40744_017_0073_3
crossref_primary_10_1016_j_rgmxen_2020_10_007
crossref_primary_10_32708_uutfd_1588058
crossref_primary_10_1016_j_idc_2017_10_004
crossref_primary_10_1093_ibd_izab037
crossref_primary_10_1007_s13555_024_01203_2
crossref_primary_10_1038_s41584_023_01062_9
crossref_primary_10_1093_rheumatology_key287
crossref_primary_10_3390_ijms241210290
crossref_primary_10_1007_s00508_022_02062_7
crossref_primary_10_1111_myc_12621
crossref_primary_10_1080_17512433_2023_2193682
crossref_primary_10_1016_j_riam_2019_09_001
crossref_primary_10_58838_2075_1230_2024_102_5_22_29
crossref_primary_10_1016_S1297_319X_19_30154_X
crossref_primary_10_1093_ecco_jcc_jjaa233
crossref_primary_10_3389_fimmu_2019_02847
crossref_primary_10_1186_s41927_018_0042_7
crossref_primary_10_1007_s13365_020_00857_w
crossref_primary_10_1097_MD_0000000000034652
crossref_primary_10_3389_fphar_2022_896167
crossref_primary_10_1080_09546634_2020_1735615
crossref_primary_10_3390_ijms222212580
crossref_primary_10_1016_j_cmi_2018_02_009
crossref_primary_10_1111_1756_185X_13130
crossref_primary_10_1177_1759720X20930116
crossref_primary_10_1007_s12664_023_01434_9
crossref_primary_10_1080_09546634_2019_1577549
crossref_primary_10_1016_j_jaad_2017_12_019
crossref_primary_10_1016_j_autrev_2025_103758
crossref_primary_10_1016_j_idc_2020_02_011
crossref_primary_10_1136_rmdopen_2022_002726
crossref_primary_10_1093_rheumatology_key276
crossref_primary_10_1186_s12876_024_03336_2
crossref_primary_10_1186_s13075_019_1866_2
crossref_primary_10_1016_j_idc_2020_02_010
crossref_primary_10_1111_ajt_16456
crossref_primary_10_1093_rheumatology_keab647
crossref_primary_10_1016_j_ccm_2023_06_007
crossref_primary_10_1038_s41598_020_69228_z
crossref_primary_10_1111_apt_18318
crossref_primary_10_51821_87_2_11812
crossref_primary_10_1016_j_crphar_2022_100096
crossref_primary_10_1016_j_idc_2020_02_014
crossref_primary_10_1136_rmdopen_2020_001395
crossref_primary_10_7705_biomedica_6239
crossref_primary_10_1007_s40257_018_0413_2
crossref_primary_10_1016_j_rgmx_2020_10_001
crossref_primary_10_2217_imt_2018_0113
crossref_primary_10_2217_imt_2017_0118
crossref_primary_10_2147_OARRR_S260426
crossref_primary_10_1093_rheumatology_keaa557
crossref_primary_10_1097_RHU_0000000000001017
crossref_primary_10_1007_s40257_022_00720_0
crossref_primary_10_1007_s10067_022_06205_z
crossref_primary_10_1007_s40744_018_0097_3
crossref_primary_10_1016_j_jaci_2020_10_022
crossref_primary_10_1016_j_semarthrit_2022_152120
crossref_primary_10_3346_jkms_2021_36_e70
crossref_primary_10_4155_fmc_2022_0032
crossref_primary_10_1513_AnnalsATS_202212_1019ST
crossref_primary_10_1007_s12664_023_01507_9
crossref_primary_10_1016_j_rcreu_2020_12_005
crossref_primary_10_1136_annrheumdis_2016_210457
crossref_primary_10_2340_actadv_v103_4536
crossref_primary_10_1136_rmdopen_2023_003946
crossref_primary_10_3389_fimmu_2025_1494283
crossref_primary_10_1002_vms3_70000
crossref_primary_10_1055_a_2246_6536
crossref_primary_10_5009_gnl19209
crossref_primary_10_14309_crj_0000000000001066
crossref_primary_10_1007_s40744_020_00258_9
crossref_primary_10_1038_nrd_2017_162
crossref_primary_10_1136_ard_2022_223335
crossref_primary_10_1093_rheumatology_keaa702
crossref_primary_10_1038_s41392_021_00791_1
crossref_primary_10_3390_pharmaceutics13050740
crossref_primary_10_1080_17474124_2018_1503052
crossref_primary_10_1136_flgastro_2023_102400
crossref_primary_10_1016_j_gastrohep_2020_04_006
crossref_primary_10_1111_vcp_12777
Cites_doi 10.1186/1476-9255-7-41
10.1093/cid/ciu104
10.1136/ard.2010.137422
10.1016/j.rdc.2012.08.019
10.1371/journal.pcbi.0030194
10.1086/424455
10.1086/587989
10.1038/nrrheum.2013.82
10.1002/pds.2049
10.1002/art.20009
10.1089/1079990041689665
10.1002/acr.20494
10.1002/art.21137
10.1136/ard.2011.152769
10.1016/j.rdc.2009.03.008
10.1097/01.tp.0000177643.05739.cd
10.1136/annrheumdis-2011-200690
10.1038/nrrheum.2009.105
10.1002/art.21978
10.1056/NEJMoa1112072
10.1002/art.33383
10.1002/art.37816
10.1086/598331
10.1136/ard.2009.118935
10.1002/art.21043
10.1136/annrheumdis-2013-204960
10.1086/383317
10.1002/art.23285
10.1002/art.38745
10.1002/art.33419
10.1136/ard.2008.089276
10.1093/infdis/jis269
10.1056/NEJMoa1310476
10.3109/14397595.2014.995875
10.1136/annrheumdis-2011-201244
10.1002/art.21705
10.1136/annrheumdis-2012-202442
10.1136/annrheumdis-2011-200163
10.1056/NEJMoa1109071
10.1136/annrheumdis-2012-201979
10.1098/rstb.2013.0428
10.7326/0003-4819-159-4-201308200-00006
10.1002/art.24567
10.1136/ard.2011.151043
10.1136/annrheumdis-2013-204575
10.1002/art.24632
10.1002/acr.21788
10.1002/acr.20567
10.1086/429999
ContentType Journal Article
Copyright Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing
Copyright: 2016 Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/ 2016
Copyright_xml – notice: Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing
– notice: Copyright: 2016 Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing
– notice: Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/ 2016
DBID 9YT
ACMMV
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7X7
7XB
88E
88I
8AF
8FE
8FH
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BBNVY
BENPR
BHPHI
BTHHO
CCPQU
DWQXO
FYUFA
GHDGH
GNUQQ
HCIFZ
K9-
K9.
LK8
M0R
M0S
M1P
M2P
M7P
PHGZM
PHGZT
PJZUB
PKEHL
PPXIY
PQEST
PQGLB
PQQKQ
PQUKI
Q9U
7X8
5PM
DOI 10.1136/annrheumdis-2015-207319
DatabaseName BMJ Open Access Journals
BMJ Journals:Open Access
CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
Science Database (Alumni Edition)
STEM Database
ProQuest SciTech Collection
ProQuest Natural Science Collection
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
Biological Science Collection
ProQuest Central
Natural Science Collection
BMJ Journals
ProQuest One
ProQuest Central Korea
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
SciTech Premium Collection
Consumer Health Database (Alumni Edition)
ProQuest Health & Medical Complete (Alumni)
ProQuest Biological Science Collection
Consumer Health Database
ProQuest Health & Medical Collection
Medical Database
Science Database
Biological Science Database
ProQuest Central Premium
ProQuest One Academic (New)
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Applied & Life Sciences
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central Basic
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
ProQuest Central Student
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest AP Science
ProQuest Central (Alumni Edition)
SciTech Premium Collection
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Natural Science Collection
ProQuest Family Health (Alumni Edition)
ProQuest Central
ProQuest One Applied & Life Sciences
ProQuest Health & Medical Research Collection
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
Natural Science Collection
ProQuest Central Korea
Health & Medical Research Collection
Biological Science Collection
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest Science Journals (Alumni Edition)
ProQuest Biological Science Collection
ProQuest Central Basic
ProQuest Science Journals
ProQuest Family Health
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
Biological Science Database
ProQuest SciTech Collection
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
BMJ Journals
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList ProQuest Central Student
MEDLINE - Academic

MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 3
  dbid: ACMMV
  name: BMJ Journals:Open Access
  url: https://journals.bmj.com/
  sourceTypes: Publisher
– sequence: 4
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1468-2060
EndPage 1138
ExternalDocumentID PMC4893093
4078252801
26318385
10_1136_annrheumdis_2015_207319
annrheumdis
Genre Journal Article
Review
GeographicLocations United States--US
Japan
GeographicLocations_xml – name: United States--US
– name: Japan
GroupedDBID ---
.55
.GJ
.VT
169
23M
2WC
39C
3O-
4.4
40O
53G
5GY
5RE
5VS
6J9
7X7
7~S
88E
88I
8AF
8FE
8FH
8FI
8FJ
8R4
8R5
9YT
AAHLL
AAKAS
AAOJX
AAWJN
AAWTL
AAXUO
ABAAH
ABJNI
ABKDF
ABMQD
ABOCM
ABTFR
ABUWG
ABVAJ
ACGFO
ACGFS
ACGOD
ACGTL
ACHTP
ACMFJ
ACMMV
ACOAB
ACOFX
ACPRK
ACQSR
ACTZY
ADBBV
ADCEG
ADFRT
ADUGQ
ADZCM
AEKJL
AENEX
AFKRA
AFWFF
AGQPQ
AHMBA
AHNKE
AHQMW
AJYBZ
AKKEP
ALIPV
ALMA_UNASSIGNED_HOLDINGS
ASPBG
AVWKF
AZFZN
AZQEC
BAWUL
BBNVY
BENPR
BHPHI
BKNYI
BLJBA
BOMFT
BPHCQ
BTFSW
BTHHO
BVXVI
C1A
C45
CAG
CCPQU
COF
CS3
CXRWF
DIK
DWQXO
E3Z
EBS
EJD
F5P
FDB
FYUFA
GNUQQ
H13
HAJ
HCIFZ
HMCUK
HYE
HZ~
IAO
IEA
IHR
INH
INR
IOF
ITC
J5H
K9-
KQ8
L7B
LK8
M0R
M1P
M2P
M7P
N9A
NTWIH
NXWIF
O9-
OK1
OVD
P2P
PHGZT
PQQKQ
PROAC
PSQYO
Q2X
R53
RHI
RMJ
RPM
RV8
RWL
RXW
TAE
TEORI
TR2
UAW
UKHRP
UYXKK
V24
VM9
VVN
W2D
W8F
WH7
WOQ
X6Y
X7M
YFH
YOC
YQY
ZGI
ZXP
AAFWJ
AALRI
AAYXX
CITATION
PHGZM
0R~
3V.
CGR
CUY
CVF
ECM
EIF
FRP
IGG
NPM
PKN
RHF
7XB
8FK
K9.
PJZUB
PKEHL
PPXIY
PQEST
PQGLB
PQUKI
Q9U
7X8
5PM
ID FETCH-LOGICAL-b488t-1ed927b5c6b2227b92346ee608b763798618e8cca2521df27f277aed35b1f0a53
IEDL.DBID 9YT
ISSN 0003-4967
1468-2060
IngestDate Thu Aug 21 18:16:04 EDT 2025
Thu Jul 10 21:41:24 EDT 2025
Fri Jul 25 11:04:46 EDT 2025
Sat Feb 15 01:21:15 EST 2025
Thu Apr 24 22:52:01 EDT 2025
Tue Jul 01 04:18:00 EDT 2025
Thu Apr 24 23:06:54 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 6
Keywords DMARDs (synthetic)
Infections
Treatment
Tuberculosis
Rheumatoid Arthritis
Language English
License This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-b488t-1ed927b5c6b2227b92346ee608b763798618e8cca2521df27f277aed35b1f0a53
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
Handling editor Tore K Kvien
ORCID 0000-0002-2731-9180
OpenAccessLink http://dx.doi.org/10.1136/annrheumdis-2015-207319
PMID 26318385
PQID 1793808786
PQPubID 2041045
PageCount 6
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_4893093
proquest_miscellaneous_1788537026
proquest_journals_1793808786
pubmed_primary_26318385
crossref_primary_10_1136_annrheumdis_2015_207319
crossref_citationtrail_10_1136_annrheumdis_2015_207319
bmj_primary_10_1136_annrheumdis_2015_207319
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2016-06-01
PublicationDateYYYYMMDD 2016-06-01
PublicationDate_xml – month: 06
  year: 2016
  text: 2016-06-01
  day: 01
PublicationDecade 2010
PublicationPlace England
PublicationPlace_xml – name: England
– name: Kidlington
– name: BMA House, Tavistock Square, London, WC1H 9JR
PublicationSeriesTitle Extended report
PublicationTitle Annals of the rheumatic diseases
PublicationTitleAlternate Ann Rheum Dis
PublicationYear 2016
Publisher Elsevier Limited
BMJ Publishing Group
Publisher_xml – name: Elsevier Limited
– name: BMJ Publishing Group
References Malmgaard 2004; 24
Winthrop 2012; 38
Winthrop, Yamanaka, Valdez 2014; 66
Marino, Sud, Plessner 2007; 3
Wollenhaupt, Silverfield, Lee 2012; 64
Wallis 2008; 58
Askling, Fored, Brandt 2005; 52
Fleischmann, Kremer, Cush 2012; 367
Hsia, Cush, Matteson 2013; 65
McInnes, Kim, Lee 2014; 73
Greenberg, Reed, Kremer 2010; 69
Arkema, Jonsson, Baecklund 2015; 74
Lee, Fleischmann, Hall 2014; 370
Tubach, Salmon, Ravaud 2009; 60
Kremer, Cohen, Wilkinson 2012; 64
Paniagua, Si, Flores 2005; 80
McDonald, Zeringue, Caplan 2009; 48
Galloway, Hyrich, Mercer 2011; 70
van Vollenhoven, Fleischmann, Cohen 2012; 367
Wolfe, Michaud, Anderson 2004; 50
Acevedo-Vasquez, Ponce de Leon, Gamboa-Cardena 2009; 35
Carmona, Gomez-Reino, Rodriguez-Valverde 2005; 52
Abel, El-Baghdadi, Bousfiha 2014; 369
Winthrop, Baxter, Liu 2013; 72
2000; 49(RR06)
Winthrop, Iseman 2013; 9
Kremer, Bloom, Breedveld 2009; 60
2011
van der Heijde, Tanaka, Fleischmann 2013; 65
Novosad, Winthrop 2014; 58
Maiga, Lun, Guo 2012; 205
Kremer, Li, Hall 2013; 159
Dixon, Watson, Lunt 2006; 54
Winthrop, Yamashita, Beekmann 2008; 46
Meyer, Jesson, Li 2010; 7
Salmon-Ceron, Tubach, Lortholary 2011; 70
Jick, Lieberman, Rahman 2006; 55
Dixon, Hyrich, Watson 2010; 69
Burmester, Panaccione, Gordon 2013; 72
Winthrop, Weinblatt, Daley 2012; 71
Strangfeld, Eveslage, Schneider 2011; 70
Tanaka, Suzuki, Nakamura 2011; 63
Winthrop, Calabrese 2011; 70
Winthrop, Chiller 2009; 5
Yamanaka, Tanaka, Takeuchi 2011; 63
Deepe 2005; 41
Winthrop, Baxter, Liu 2011; 20
Wallis, Broder, Wong 2004; 39
Wallis, Broder, Wong 2004; 38
Fleischmann, Cutolo, Genovese 2012; 64
Tanaka, Takeuchi, Yamanaka 2015; 25
Ramiro, Gaujoux-Viala, Nam 2014; 73
Winthrop (10.1136/annrheumdis-2015-207319_bib4) 2013; 9
(10.1136/annrheumdis-2015-207319_bib53) 2000; 49(RR06)
Wollenhaupt (10.1136/annrheumdis-2015-207319_bib24) 2012; 64
Malmgaard (10.1136/annrheumdis-2015-207319_bib52) 2004; 24
Wallis (10.1136/annrheumdis-2015-207319_bib6) 2004; 39
Tanaka (10.1136/annrheumdis-2015-207319_bib15) 2011; 63
Winthrop (10.1136/annrheumdis-2015-207319_bib34) 2013; 72
Galloway (10.1136/annrheumdis-2015-207319_bib47) 2011; 70
10.1136/annrheumdis-2015-207319_bib10
Wolfe (10.1136/annrheumdis-2015-207319_bib33) 2004; 50
Winthrop (10.1136/annrheumdis-2015-207319_bib41) 2008; 46
Maiga (10.1136/annrheumdis-2015-207319_bib51) 2012; 205
Dixon (10.1136/annrheumdis-2015-207319_bib42) 2010; 69
Yamanaka (10.1136/annrheumdis-2015-207319_bib25) 2011; 63
Salmon-Ceron (10.1136/annrheumdis-2015-207319_bib29) 2011; 70
van Vollenhoven (10.1136/annrheumdis-2015-207319_bib22) 2012; 367
Hsia (10.1136/annrheumdis-2015-207319_bib37) 2013; 65
Novosad (10.1136/annrheumdis-2015-207319_bib1) 2014; 58
Ramiro (10.1136/annrheumdis-2015-207319_bib2) 2014; 73
Kremer (10.1136/annrheumdis-2015-207319_bib12) 2012; 64
Arkema (10.1136/annrheumdis-2015-207319_bib35) 2015; 74
Abel (10.1136/annrheumdis-2015-207319_bib50) 2014; 369
Wallis (10.1136/annrheumdis-2015-207319_bib7) 2004; 38
van der Heijde (10.1136/annrheumdis-2015-207319_bib21) 2013; 65
Tanaka (10.1136/annrheumdis-2015-207319_bib16) 2015; 25
Lee (10.1136/annrheumdis-2015-207319_bib23) 2014; 370
Winthrop (10.1136/annrheumdis-2015-207319_bib48) 2014; 66
Dixon (10.1136/annrheumdis-2015-207319_bib28) 2006; 54
Deepe (10.1136/annrheumdis-2015-207319_bib5) 2005; 41
10.1136/annrheumdis-2015-207319_bib26
Meyer (10.1136/annrheumdis-2015-207319_bib11) 2010; 7
Winthrop (10.1136/annrheumdis-2015-207319_bib44) 2011; 70
McInnes (10.1136/annrheumdis-2015-207319_bib17) 2014; 73
Carmona (10.1136/annrheumdis-2015-207319_bib31) 2005; 52
Strangfeld (10.1136/annrheumdis-2015-207319_bib46) 2011; 70
Jick (10.1136/annrheumdis-2015-207319_bib3) 2006; 55
Kremer (10.1136/annrheumdis-2015-207319_bib13) 2009; 60
Acevedo-Vasquez (10.1136/annrheumdis-2015-207319_bib38) 2009; 35
Winthrop (10.1136/annrheumdis-2015-207319_bib39) 2012; 71
Paniagua (10.1136/annrheumdis-2015-207319_bib49) 2005; 80
Tubach (10.1136/annrheumdis-2015-207319_bib36) 2009; 60
Winthrop (10.1136/annrheumdis-2015-207319_bib43) 2011; 20
Fleischmann (10.1136/annrheumdis-2015-207319_bib20) 2012; 367
Fleischmann (10.1136/annrheumdis-2015-207319_bib14) 2012; 64
Wallis (10.1136/annrheumdis-2015-207319_bib40) 2008; 58
Burmester (10.1136/annrheumdis-2015-207319_bib18) 2013; 72
Winthrop (10.1136/annrheumdis-2015-207319_bib30) 2012; 38
Askling (10.1136/annrheumdis-2015-207319_bib32) 2005; 52
McDonald (10.1136/annrheumdis-2015-207319_bib45) 2009; 48
Kremer (10.1136/annrheumdis-2015-207319_bib19) 2013; 159
Greenberg (10.1136/annrheumdis-2015-207319_bib27) 2010; 69
Marino (10.1136/annrheumdis-2015-207319_bib8) 2007; 3
Winthrop (10.1136/annrheumdis-2015-207319_bib9) 2009; 5
References_xml – volume: 7
  start-page: 41
  year: 2010
  article-title: Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis
  publication-title: J Inflamm (Lond)
  doi: 10.1186/1476-9255-7-41
– volume: 58
  start-page: 1587
  year: 2014
  article-title: Beyond tumor necrosis factor inhibition: the expanding pipeline of biologic therapies for inflammatory diseases and their associated infectious sequelae
  publication-title: Clin Infect Dis
  doi: 10.1093/cid/ciu104
– volume: 70
  start-page: 616
  year: 2011
  article-title: Drug-specific risk of non-tuberculosis opportunistic infections in patients receiving anti-TNF therapy reported to the 3-year prospective French RATIO registry
  publication-title: Ann Rheum Dis
  doi: 10.1136/ard.2010.137422
– volume: 38
  start-page: 727
  year: 2012
  article-title: Infections and biologic therapy in rheumatoid arthritis: our changing understanding of risk and prevention
  publication-title: Rheum Dis Clin North Am
  doi: 10.1016/j.rdc.2012.08.019
– volume: 3
  start-page: 1909
  year: 2007
  article-title: Differences in reactivation of tuberculosis induced from anti-TNF treatments are based on bioavailability in granulomatous tissue
  publication-title: PLoS Comput Biol
  doi: 10.1371/journal.pcbi.0030194
– volume: 39
  start-page: 1254
  year: 2004
  article-title: Granulomatous infections due to tumor necrosis factor blockade: correction
  publication-title: Clin Infect Dis
  doi: 10.1086/424455
– volume: 46
  start-page: 1738
  year: 2008
  article-title: Mycobacterial and other serious infections in patients receiving anti-tumor necrosis factor and other newly approved biologic therapies: case finding through the Emerging Infections Network
  publication-title: Clin Infect Dis
  doi: 10.1086/587989
– volume: 9
  start-page: 524
  year: 2013
  article-title: Bedfellows: mycobacteria and rheumatoid arthritis in the era of biologic therapy
  publication-title: Nat Rev Rheumatol
  doi: 10.1038/nrrheum.2013.82
– volume: 20
  start-page: 229
  year: 2011
  article-title: The reliability of diagnostic coding and laboratory data to identify tuberculosis and nontuberculous mycobacterial disease among rheumatoid arthritis patients using anti-tumor necrosis factor therapy
  publication-title: Pharmacoepidemiol Drug Saf
  doi: 10.1002/pds.2049
– volume: 50
  start-page: 372
  year: 2004
  article-title: Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy
  publication-title: Arthritis Rheum
  doi: 10.1002/art.20009
– volume: 24
  start-page: 439
  year: 2004
  article-title: Induction and regulation of IFNs during viral infections
  publication-title: J Interferon Cytokine Res
  doi: 10.1089/1079990041689665
– volume: 63
  start-page: 1150
  year: 2011
  article-title: Phase II study of tofacitinib (CP-690,550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate
  publication-title: Arthritis Care Res (Hoboken)
  doi: 10.1002/acr.20494
– volume: 52
  start-page: 1986
  year: 2005
  article-title: Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden
  publication-title: Arthritis Rheum
  doi: 10.1002/art.21137
– volume: 70
  start-page: 1810
  year: 2011
  article-title: Risk of septic arthritis in patients with rheumatoid arthritis and the effect of anti-TNF therapy: results from the British Society for Rheumatology Biologics Register
  publication-title: Ann Rheum Dis
  doi: 10.1136/ard.2011.152769
– volume: 35
  start-page: 163
  year: 2009
  article-title: Latent infection and tuberculosis disease in rheumatoid arthritis patients
  publication-title: Rheum Dis Clin North Am
  doi: 10.1016/j.rdc.2009.03.008
– volume: 80
  start-page: 1283
  year: 2005
  article-title: Effects of JAK3 inhibition with CP-690,550 on immune cell populations and their functions in nonhuman primate recipients of kidney allografts
  publication-title: Transplantation
  doi: 10.1097/01.tp.0000177643.05739.cd
– volume: 72
  start-page: 37
  year: 2013
  article-title: Mycobacterial diseases and antitumour necrosis factor therapy in USA
  publication-title: Ann Rheum Dis
  doi: 10.1136/annrheumdis-2011-200690
– volume: 5
  start-page: 405
  year: 2009
  article-title: Preventing and treating biologic-associated opportunistic infections
  publication-title: Nat Rev Rheumatol
  doi: 10.1038/nrrheum.2009.105
– year: 2011
  article-title: Global tuberculosis control: WHO report
– volume: 54
  start-page: 2368
  year: 2006
  article-title: Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register
  publication-title: Arthritis Rheum
  doi: 10.1002/art.21978
– volume: 367
  start-page: 508
  year: 2012
  article-title: Tofacitinib or adalimumab versus placebo in rheumatoid arthritis
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1112072
– volume: 64
  start-page: 617
  year: 2012
  article-title: Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs
  publication-title: Arthritis Rheum
  doi: 10.1002/art.33383
– volume: 65
  start-page: 559
  year: 2013
  article-title: Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study
  publication-title: Arthritis Rheum
  doi: 10.1002/art.37816
– volume: 48
  start-page: 1364
  year: 2009
  article-title: Herpes zoster risk factors in a national cohort of veterans with rheumatoid arthritis
  publication-title: Clin Infect Dis
  doi: 10.1086/598331
– volume: 69
  start-page: 522
  year: 2010
  article-title: Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR)
  publication-title: Ann Rheum Dis
  doi: 10.1136/ard.2009.118935
– volume: 52
  start-page: 1766
  year: 2005
  article-title: Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists
  publication-title: Arthritis Rheum
  doi: 10.1002/art.21043
– volume: 74
  start-page: 1212
  year: 2015
  article-title: Are patients with rheumatoid arthritis still at an increased risk of tuberculosis and what is the role of biological treatments?
  publication-title: Ann Rheum Dis
  doi: 10.1136/annrheumdis-2013-204960
– volume: 38
  start-page: 1261
  year: 2004
  article-title: Granulomatous infectious diseases associated with tumor necrosis factor antagonists
  publication-title: Clin Infect Dis
  doi: 10.1086/383317
– volume: 58
  start-page: 947
  year: 2008
  article-title: Mathematical modeling of the cause of tuberculosis during tumor necrosis factor blockade
  publication-title: Arthritis Rheum
  doi: 10.1002/art.23285
– volume: 66
  start-page: 2675
  year: 2014
  article-title: Herpes zoster and tofacitinib therapy in patients with rheumatoid arthritis
  publication-title: Arthritis Rheumatol
  doi: 10.1002/art.38745
– volume: 64
  start-page: 970
  year: 2012
  article-title: A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone
  publication-title: Arthritis Rheum
  doi: 10.1002/art.33419
– volume: 69
  start-page: 380
  year: 2010
  article-title: Association of methotrexate and tumour necrosis factor antagonists with risk of infectious outcomes including opportunistic infections in the CORRONA registry
  publication-title: Ann Rheum Dis
  doi: 10.1136/ard.2008.089276
– volume: 205
  start-page: 1705
  year: 2012
  article-title: Risk of tuberculosis reactivation with tofacitinib (CP-690550)
  publication-title: J Infect Dis
  doi: 10.1093/infdis/jis269
– volume: 370
  start-page: 2377
  year: 2014
  article-title: Tofacitinib versus Methotrexate in Rheumatoid Arthritis
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1310476
– volume: 49(RR06)
  start-page: 1
  year: 2000
  article-title: Targeted tuberculin testing and treatment of latent tuberculosis infection
  publication-title: MMWR
– volume: 25
  start-page: 514
  year: 2015
  article-title: Efficacy and safety of tofacitinib as monotherapy in Japanese patients with active rheumatoid arthritis: a 12-week, randomized, phase 2 study
  publication-title: Mod Rheumatol
  doi: 10.3109/14397595.2014.995875
– volume: 72
  start-page: 517
  year: 2013
  article-title: Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease
  publication-title: Ann Rheum Dis
  doi: 10.1136/annrheumdis-2011-201244
– volume: 55
  start-page: 19
  year: 2006
  article-title: Glucocorticoid use, other associated factors, and the risk of tuberculosis
  publication-title: Arthritis Rheum
  doi: 10.1002/art.21705
– volume: 73
  start-page: 124
  year: 2014
  article-title: Open-label tofacitinib and double-blind atorvastatin in rheumatoid arthritis patients: a randomised study
  publication-title: Ann Rheum Dis
  doi: 10.1136/annrheumdis-2012-202442
– volume: 70
  start-page: 1701
  year: 2011
  article-title: Let the fog be lifted: screening for hepatitis B virus before biological therapy
  publication-title: Ann Rheum Dis
  doi: 10.1136/annrheumdis-2011-200163
– volume: 367
  start-page: 495
  year: 2012
  article-title: Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1109071
– volume: 71
  start-page: 1757
  year: 2012
  article-title: You can't always get what you want, but if you try sometimes (with two tests—TST and IGRA—for tuberculosis) you get what you need
  publication-title: Ann Rheum Dis
  doi: 10.1136/annrheumdis-2012-201979
– volume: 369
  start-page: 20130428
  year: 2014
  article-title: Human genetics of tuberculosis: a long and winding road
  publication-title: Philos Trans R Soc Lond B Biol Sci
  doi: 10.1098/rstb.2013.0428
– volume: 159
  start-page: 253
  year: 2013
  article-title: Tofacitinib in Combination with Nonbiologic DMARDs in Patients with Active Rheumatoid Arthritis: A Randomized Trial
  publication-title: Ann Intern Med
  doi: 10.7326/0003-4819-159-4-201308200-00006
– volume: 60
  start-page: 1895
  year: 2009
  article-title: The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo
  publication-title: Arthritis Rheum
  doi: 10.1002/art.24567
– volume: 64
  start-page: S548
  issue: (Suppl 10)
  year: 2012
  article-title: Tofacitinib, an oral janus kinase inhibitor, in the treatment of rheumatoid arthritis: open-label, long-term extension safety and efficacy up to 48 months [abstract]
  publication-title: Arthritis Rheum
– volume: 70
  start-page: 1914
  year: 2011
  article-title: Treatment benefit or survival of the fittest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient?
  publication-title: Ann Rheum Dis
  doi: 10.1136/ard.2011.151043
– volume: 73
  start-page: 529
  year: 2014
  article-title: Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis
  publication-title: Ann Rheum Dis
  doi: 10.1136/annrheumdis-2013-204575
– volume: 60
  start-page: 1884
  year: 2009
  article-title: Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: the three-year prospective French Research Axed on Tolerance of Biotherapies registry
  publication-title: Arthritis Rheum
  doi: 10.1002/art.24632
– volume: 65
  start-page: 309
  year: 2013
  article-title: Comprehensive tuberculosis screening program in patients with inflammatory arthritides treated with golimumab, a human anti-tumor necrosis factor antibody, in Phase III clinical trials
  publication-title: Arthritis Care Res (Hoboken)
  doi: 10.1002/acr.21788
– volume: 63
  start-page: S473
  year: 2011
  article-title: An oral janus kinase inhibitor, as monotherapy or with background methotrexate in japanese patients with rheumatoid arthritis: a phase 2/3 long-term extension study [abstract]
  publication-title: Arthritis Rheum
  doi: 10.1002/acr.20567
– volume: 41
  start-page: S204
  issue: (Suppl 3)
  year: 2005
  article-title: Modulation of infection with Histoplasma capsulatum by inhibition of tumor necrosis factor-alpha activity
  publication-title: Clin Infect Dis
  doi: 10.1086/429999
– volume: 63
  start-page: 1150
  year: 2011
  ident: 10.1136/annrheumdis-2015-207319_bib15
  article-title: Phase II study of tofacitinib (CP-690,550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate
  publication-title: Arthritis Care Res (Hoboken)
  doi: 10.1002/acr.20494
– volume: 64
  start-page: 970
  year: 2012
  ident: 10.1136/annrheumdis-2015-207319_bib12
  article-title: A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone
  publication-title: Arthritis Rheum
  doi: 10.1002/art.33419
– volume: 65
  start-page: 309
  year: 2013
  ident: 10.1136/annrheumdis-2015-207319_bib37
  article-title: Comprehensive tuberculosis screening program in patients with inflammatory arthritides treated with golimumab, a human anti-tumor necrosis factor antibody, in Phase III clinical trials
  publication-title: Arthritis Care Res (Hoboken)
  doi: 10.1002/acr.21788
– volume: 64
  start-page: S548
  issue: Suppl 10
  year: 2012
  ident: 10.1136/annrheumdis-2015-207319_bib24
  article-title: Tofacitinib, an oral janus kinase inhibitor, in the treatment of rheumatoid arthritis: open-label, long-term extension safety and efficacy up to 48 months [abstract]
  publication-title: Arthritis Rheum
– volume: 69
  start-page: 522
  year: 2010
  ident: 10.1136/annrheumdis-2015-207319_bib42
  article-title: Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR)
  publication-title: Ann Rheum Dis
  doi: 10.1136/ard.2009.118935
– volume: 20
  start-page: 229
  year: 2011
  ident: 10.1136/annrheumdis-2015-207319_bib43
  article-title: The reliability of diagnostic coding and laboratory data to identify tuberculosis and nontuberculous mycobacterial disease among rheumatoid arthritis patients using anti-tumor necrosis factor therapy
  publication-title: Pharmacoepidemiol Drug Saf
  doi: 10.1002/pds.2049
– volume: 71
  start-page: 1757
  year: 2012
  ident: 10.1136/annrheumdis-2015-207319_bib39
  article-title: You can't always get what you want, but if you try sometimes (with two tests—TST and IGRA—for tuberculosis) you get what you need
  publication-title: Ann Rheum Dis
  doi: 10.1136/annrheumdis-2012-201979
– volume: 50
  start-page: 372
  year: 2004
  ident: 10.1136/annrheumdis-2015-207319_bib33
  article-title: Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy
  publication-title: Arthritis Rheum
  doi: 10.1002/art.20009
– volume: 7
  start-page: 41
  year: 2010
  ident: 10.1136/annrheumdis-2015-207319_bib11
  article-title: Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis
  publication-title: J Inflamm (Lond)
  doi: 10.1186/1476-9255-7-41
– volume: 38
  start-page: 727
  year: 2012
  ident: 10.1136/annrheumdis-2015-207319_bib30
  article-title: Infections and biologic therapy in rheumatoid arthritis: our changing understanding of risk and prevention
  publication-title: Rheum Dis Clin North Am
  doi: 10.1016/j.rdc.2012.08.019
– volume: 70
  start-page: 616
  year: 2011
  ident: 10.1136/annrheumdis-2015-207319_bib29
  article-title: Drug-specific risk of non-tuberculosis opportunistic infections in patients receiving anti-TNF therapy reported to the 3-year prospective French RATIO registry
  publication-title: Ann Rheum Dis
  doi: 10.1136/ard.2010.137422
– volume: 367
  start-page: 508
  year: 2012
  ident: 10.1136/annrheumdis-2015-207319_bib22
  article-title: Tofacitinib or adalimumab versus placebo in rheumatoid arthritis
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1112072
– volume: 5
  start-page: 405
  year: 2009
  ident: 10.1136/annrheumdis-2015-207319_bib9
  article-title: Preventing and treating biologic-associated opportunistic infections
  publication-title: Nat Rev Rheumatol
  doi: 10.1038/nrrheum.2009.105
– volume: 367
  start-page: 495
  year: 2012
  ident: 10.1136/annrheumdis-2015-207319_bib20
  article-title: Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1109071
– volume: 35
  start-page: 163
  year: 2009
  ident: 10.1136/annrheumdis-2015-207319_bib38
  article-title: Latent infection and tuberculosis disease in rheumatoid arthritis patients
  publication-title: Rheum Dis Clin North Am
  doi: 10.1016/j.rdc.2009.03.008
– volume: 63
  start-page: S473
  year: 2011
  ident: 10.1136/annrheumdis-2015-207319_bib25
  article-title: An oral janus kinase inhibitor, as monotherapy or with background methotrexate in japanese patients with rheumatoid arthritis: a phase 2/3 long-term extension study [abstract]
  publication-title: Arthritis Rheum
– volume: 159
  start-page: 253
  year: 2013
  ident: 10.1136/annrheumdis-2015-207319_bib19
  article-title: Tofacitinib in Combination with Nonbiologic DMARDs in Patients with Active Rheumatoid Arthritis: A Randomized Trial
  publication-title: Ann Intern Med
  doi: 10.7326/0003-4819-159-4-201308200-00006
– volume: 55
  start-page: 19
  year: 2006
  ident: 10.1136/annrheumdis-2015-207319_bib3
  article-title: Glucocorticoid use, other associated factors, and the risk of tuberculosis
  publication-title: Arthritis Rheum
  doi: 10.1002/art.21705
– volume: 39
  start-page: 1254
  year: 2004
  ident: 10.1136/annrheumdis-2015-207319_bib6
  article-title: Granulomatous infections due to tumor necrosis factor blockade: correction
  publication-title: Clin Infect Dis
  doi: 10.1086/424455
– volume: 70
  start-page: 1810
  year: 2011
  ident: 10.1136/annrheumdis-2015-207319_bib47
  article-title: Risk of septic arthritis in patients with rheumatoid arthritis and the effect of anti-TNF therapy: results from the British Society for Rheumatology Biologics Register
  publication-title: Ann Rheum Dis
  doi: 10.1136/ard.2011.152769
– volume: 69
  start-page: 380
  year: 2010
  ident: 10.1136/annrheumdis-2015-207319_bib27
  article-title: Association of methotrexate and tumour necrosis factor antagonists with risk of infectious outcomes including opportunistic infections in the CORRONA registry
  publication-title: Ann Rheum Dis
  doi: 10.1136/ard.2008.089276
– volume: 80
  start-page: 1283
  year: 2005
  ident: 10.1136/annrheumdis-2015-207319_bib49
  article-title: Effects of JAK3 inhibition with CP-690,550 on immune cell populations and their functions in nonhuman primate recipients of kidney allografts
  publication-title: Transplantation
  doi: 10.1097/01.tp.0000177643.05739.cd
– volume: 370
  start-page: 2377
  year: 2014
  ident: 10.1136/annrheumdis-2015-207319_bib23
  article-title: Tofacitinib versus Methotrexate in Rheumatoid Arthritis
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1310476
– volume: 60
  start-page: 1884
  year: 2009
  ident: 10.1136/annrheumdis-2015-207319_bib36
  article-title: Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: the three-year prospective French Research Axed on Tolerance of Biotherapies registry
  publication-title: Arthritis Rheum
  doi: 10.1002/art.24632
– volume: 52
  start-page: 1986
  year: 2005
  ident: 10.1136/annrheumdis-2015-207319_bib32
  article-title: Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden
  publication-title: Arthritis Rheum
  doi: 10.1002/art.21137
– volume: 48
  start-page: 1364
  year: 2009
  ident: 10.1136/annrheumdis-2015-207319_bib45
  article-title: Herpes zoster risk factors in a national cohort of veterans with rheumatoid arthritis
  publication-title: Clin Infect Dis
  doi: 10.1086/598331
– volume: 54
  start-page: 2368
  year: 2006
  ident: 10.1136/annrheumdis-2015-207319_bib28
  article-title: Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register
  publication-title: Arthritis Rheum
  doi: 10.1002/art.21978
– volume: 58
  start-page: 947
  year: 2008
  ident: 10.1136/annrheumdis-2015-207319_bib40
  article-title: Mathematical modeling of the cause of tuberculosis during tumor necrosis factor blockade
  publication-title: Arthritis Rheum
  doi: 10.1002/art.23285
– volume: 205
  start-page: 1705
  year: 2012
  ident: 10.1136/annrheumdis-2015-207319_bib51
  article-title: Risk of tuberculosis reactivation with tofacitinib (CP-690550)
  publication-title: J Infect Dis
  doi: 10.1093/infdis/jis269
– volume: 49(RR06)
  start-page: 1
  year: 2000
  ident: 10.1136/annrheumdis-2015-207319_bib53
  article-title: Targeted tuberculin testing and treatment of latent tuberculosis infection
  publication-title: MMWR
– volume: 72
  start-page: 37
  year: 2013
  ident: 10.1136/annrheumdis-2015-207319_bib34
  article-title: Mycobacterial diseases and antitumour necrosis factor therapy in USA
  publication-title: Ann Rheum Dis
  doi: 10.1136/annrheumdis-2011-200690
– volume: 41
  start-page: S204
  issue: Suppl 3
  year: 2005
  ident: 10.1136/annrheumdis-2015-207319_bib5
  article-title: Modulation of infection with Histoplasma capsulatum by inhibition of tumor necrosis factor-alpha activity
  publication-title: Clin Infect Dis
  doi: 10.1086/429999
– ident: 10.1136/annrheumdis-2015-207319_bib10
– volume: 60
  start-page: 1895
  year: 2009
  ident: 10.1136/annrheumdis-2015-207319_bib13
  article-title: The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo
  publication-title: Arthritis Rheum
  doi: 10.1002/art.24567
– volume: 46
  start-page: 1738
  year: 2008
  ident: 10.1136/annrheumdis-2015-207319_bib41
  article-title: Mycobacterial and other serious infections in patients receiving anti-tumor necrosis factor and other newly approved biologic therapies: case finding through the Emerging Infections Network
  publication-title: Clin Infect Dis
  doi: 10.1086/587989
– volume: 64
  start-page: 617
  year: 2012
  ident: 10.1136/annrheumdis-2015-207319_bib14
  article-title: Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs
  publication-title: Arthritis Rheum
  doi: 10.1002/art.33383
– volume: 52
  start-page: 1766
  year: 2005
  ident: 10.1136/annrheumdis-2015-207319_bib31
  article-title: Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists
  publication-title: Arthritis Rheum
  doi: 10.1002/art.21043
– volume: 74
  start-page: 1212
  year: 2015
  ident: 10.1136/annrheumdis-2015-207319_bib35
  article-title: Are patients with rheumatoid arthritis still at an increased risk of tuberculosis and what is the role of biological treatments?
  publication-title: Ann Rheum Dis
  doi: 10.1136/annrheumdis-2013-204960
– volume: 72
  start-page: 517
  year: 2013
  ident: 10.1136/annrheumdis-2015-207319_bib18
  article-title: Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease
  publication-title: Ann Rheum Dis
  doi: 10.1136/annrheumdis-2011-201244
– volume: 24
  start-page: 439
  year: 2004
  ident: 10.1136/annrheumdis-2015-207319_bib52
  article-title: Induction and regulation of IFNs during viral infections
  publication-title: J Interferon Cytokine Res
  doi: 10.1089/1079990041689665
– ident: 10.1136/annrheumdis-2015-207319_bib26
– volume: 70
  start-page: 1701
  year: 2011
  ident: 10.1136/annrheumdis-2015-207319_bib44
  article-title: Let the fog be lifted: screening for hepatitis B virus before biological therapy
  publication-title: Ann Rheum Dis
  doi: 10.1136/annrheumdis-2011-200163
– volume: 3
  start-page: 1909
  year: 2007
  ident: 10.1136/annrheumdis-2015-207319_bib8
  article-title: Differences in reactivation of tuberculosis induced from anti-TNF treatments are based on bioavailability in granulomatous tissue
  publication-title: PLoS Comput Biol
  doi: 10.1371/journal.pcbi.0030194
– volume: 73
  start-page: 529
  year: 2014
  ident: 10.1136/annrheumdis-2015-207319_bib2
  article-title: Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis
  publication-title: Ann Rheum Dis
  doi: 10.1136/annrheumdis-2013-204575
– volume: 369
  start-page: 20130428
  year: 2014
  ident: 10.1136/annrheumdis-2015-207319_bib50
  article-title: Human genetics of tuberculosis: a long and winding road
  publication-title: Philos Trans R Soc Lond B Biol Sci
  doi: 10.1098/rstb.2013.0428
– volume: 58
  start-page: 1587
  year: 2014
  ident: 10.1136/annrheumdis-2015-207319_bib1
  article-title: Beyond tumor necrosis factor inhibition: the expanding pipeline of biologic therapies for inflammatory diseases and their associated infectious sequelae
  publication-title: Clin Infect Dis
  doi: 10.1093/cid/ciu104
– volume: 9
  start-page: 524
  year: 2013
  ident: 10.1136/annrheumdis-2015-207319_bib4
  article-title: Bedfellows: mycobacteria and rheumatoid arthritis in the era of biologic therapy
  publication-title: Nat Rev Rheumatol
  doi: 10.1038/nrrheum.2013.82
– volume: 70
  start-page: 1914
  year: 2011
  ident: 10.1136/annrheumdis-2015-207319_bib46
  article-title: Treatment benefit or survival of the fittest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient?
  publication-title: Ann Rheum Dis
  doi: 10.1136/ard.2011.151043
– volume: 66
  start-page: 2675
  year: 2014
  ident: 10.1136/annrheumdis-2015-207319_bib48
  article-title: Herpes zoster and tofacitinib therapy in patients with rheumatoid arthritis
  publication-title: Arthritis Rheumatol
  doi: 10.1002/art.38745
– volume: 65
  start-page: 559
  year: 2013
  ident: 10.1136/annrheumdis-2015-207319_bib21
  article-title: Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study
  publication-title: Arthritis Rheum
  doi: 10.1002/art.37816
– volume: 38
  start-page: 1261
  year: 2004
  ident: 10.1136/annrheumdis-2015-207319_bib7
  article-title: Granulomatous infectious diseases associated with tumor necrosis factor antagonists
  publication-title: Clin Infect Dis
  doi: 10.1086/383317
– volume: 25
  start-page: 514
  year: 2015
  ident: 10.1136/annrheumdis-2015-207319_bib16
  article-title: Efficacy and safety of tofacitinib as monotherapy in Japanese patients with active rheumatoid arthritis: a 12-week, randomized, phase 2 study
  publication-title: Mod Rheumatol
  doi: 10.3109/14397595.2014.995875
– volume: 73
  start-page: 124
  year: 2014
  ident: 10.1136/annrheumdis-2015-207319_bib17
  article-title: Open-label tofacitinib and double-blind atorvastatin in rheumatoid arthritis patients: a randomised study
  publication-title: Ann Rheum Dis
  doi: 10.1136/annrheumdis-2012-202442
SSID ssj0000818
Score 2.5776181
SecondaryResourceType review_article
Snippet ObjectivesTo evaluate the risk of opportunistic infections (OIs) in patients with rheumatoid arthritis (RA) treated with tofacitinib.MethodsPhase II, III and...
To evaluate the risk of opportunistic infections (OIs) in patients with rheumatoid arthritis (RA) treated with tofacitinib. Phase II, III and long-term...
Objectives To evaluate the risk of opportunistic infections (OIs) in patients with rheumatoid arthritis (RA) treated with tofacitinib. Methods Phase II, III...
To evaluate the risk of opportunistic infections (OIs) in patients with rheumatoid arthritis (RA) treated with tofacitinib.OBJECTIVESTo evaluate the risk of...
SourceID pubmedcentral
proquest
pubmed
crossref
bmj
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 1133
SubjectTerms Antirheumatic Agents - adverse effects
Antirheumatic Agents - therapeutic use
Arthritis, Rheumatoid - drug therapy
Arthritis, Rheumatoid - epidemiology
Arthritis, Rheumatoid - immunology
Clinical and Epidemiological Research
Clinical Trials as Topic
Cytomegalovirus
Herpes viruses
Humans
Immunocompromised Host
Immunosuppressive Agents - adverse effects
Immunosuppressive Agents - therapeutic use
Incidence
Infections
Janus Kinase 3 - antagonists & inhibitors
Kinases
Opportunistic Infections - chemically induced
Opportunistic Infections - epidemiology
Opportunistic Infections - immunology
Patients
Piperidines - adverse effects
Piperidines - therapeutic use
Pneumonia
Protein Kinase Inhibitors - adverse effects
Protein Kinase Inhibitors - therapeutic use
Pyrimidines - adverse effects
Pyrimidines - therapeutic use
Pyrroles - adverse effects
Pyrroles - therapeutic use
Regions
Rheumatoid arthritis
Risk Assessment
Steroids
Tuberculosis
Tuberculosis - chemically induced
Tuberculosis - epidemiology
Tuberculosis - immunology
Tumor necrosis factor-TNF
Viral infections
SummonAdditionalLinks – databaseName: Health & Medical Collection
  dbid: 7X7
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1La9wwEBZNCqWX0PTpNC0q9FZELT8k-RRKaQiB9JTA3oz1Yl0Se7u2_39mZHnTbaEtGGOQhKyZkTTSzHxDyEdZ-kJaWTGnvWWFloJVwmbMOl0ULs29URgofPVdXNwUl6tyFS_chuhWuayJYaG2vcE78s8oSCpVUomzzU-GWaPQuhpTaByQxwhdhi5dciUfVmLF1ZIxr6iEjP5dPA9JXrZrN93ZdgBB4SW8ZI5wOwf67sf-HvWH4vm7_-QvG9L5M3IUNUn6ZWb9MXnkuufkyVW0lb8g7fWk3dZMt_3QDrTpLA3BVrTfoMqNVmxoSBdnrG6ATzr2vjHt2HatZsEF3VkakVcHile2NAwHDuqtpSB06wCJ9JLcnH-7_nrBYmIFpmG-jow7W2VSl0ZoDIXVoOQVwjmRKuBVLisluHIKeJvB5m59JuGRjbN5qblPmzJ_RQ67vnNvCLW-AgUr09waWwitVNWkXBnvrfGgKfKEfAKC1psZOqMOR448hEEv5K-R_PVM_oSIhfC1iRjlmCrj9t8N013D_-7rdOFsHeftUD9IWUI-7IphxqEZpelcP2EdBTqOhMNrQl7PgrDrMxO4RqoyIXJPRHYVEM17v6Rr1wHVG1GA0io_-ftvvSVPYQxidlY7JYfjdnLvQC0a9fsg-_c98xBH
  priority: 102
  providerName: ProQuest
Title Tuberculosis and other opportunistic infections in tofacitinib-treated patients with rheumatoid arthritis
URI http://ard.bmj.com/content/75/6/1133.full
https://www.ncbi.nlm.nih.gov/pubmed/26318385
https://www.proquest.com/docview/1793808786
https://www.proquest.com/docview/1788537026
https://pubmed.ncbi.nlm.nih.gov/PMC4893093
Volume 75
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3ri9QwEB_uAeIX8W31XCL4TQpNH0n68TzuOIQ9RPZk_VSaJmErd-2xbf9_Z9J2dVV8QOmDJA3NzCSTzsxvAN7KzKXSyDy02pkw1VKEuTBxaKxOUxslrlIUKLy8EpfX6Yd1tj4A_nsLPk98Opbtxg63pu6QpDzDk0wI6PPYI7MQU39ZfZ98FVdzkrw0F3Jy6frDiwgOWBBnUzrlQ337dX-F-kXt_Nl78ofl6OIhPJj0SHY6Ev4RHNjmMdxbTpbyJ1CvBm231XDTdnXHysYwH2rF2jtSuMmGjQ3Z7IrVdHjL-taVVd3XTa1D74BuDZtwVztGP2yZ_zLcpteGIcttPCDSU7i-OF-dXYZTWoVQo7T2Ibcmj6XOKqEpEFajipcKa0WkkFKJzJXgyiqkbIxLu3GxxEOW1iSZ5i4qs-QZHDVtY18AMy5H9SrW3FQmFVqpvIy4qpwzlUM9kQfwDge0uBuBMwq_4Uh8EPRMiYIoUYyUCEDMA19UE0I5Jcq4-XvDaNfwn_s6mSlbTFLbFTRZqUhJJQJ4sytGeSMjStnYdqA6CjUciVvXAJ6PjLDrc-ajAOQei-wqEJb3fklTbzymN2EARXny8r8G7BXcxycxeq6dwFG_Hexr1JF6vYBDuZYLLxsLOD49Wy4_4_X9-dXHT98AvbYTSw
linkProvider BMJ Publishing Group Ltd
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Zb9QwEB6VrQS8VJxlSwEjwROKyGk7DwhxtNrS7gqhrdS3EMe2NqhNlk0ixJ_iNzKTY8uCBLxUiqJIthV7_Hk8Y88B8ExENhRaxI5RVjuhEtyJufYdbVQYGjewmSRH4emMT07DD2fR2Rb8GHxhyKxy4Ikto9ZlRmfkLwlI0pVC8tfLrw5ljaLb1SGFRgeLY_P9G6ps1auj9zi_z33_8GD-buL0WQUchWCtHc_o2BcqyrgiP1CFEk7IjeGuxI4GIpbck0biwHzc2bT1BT4iNTqIlGfdlLJEIMvfDgNUZUaw_fZg9vHTJe-Xnhxy9IUxF71FmRe0aWVWC9Nc6LxCaHoRvkRAAX6uqYsvm7viH6Lu7xabv2yBh7dgp5dd2ZsObLdhyxR34Pq0v52_C_m8UWaVNedllVcsLTRr3btYuSQhn-7NsSEbzL-KCj9ZXdo0y-u8yJXTGr0bzfpYrxWjQ2LWDiety1wzhPmiDcJ0D06vhOj3YVSUhXkATNsYRTpfeTrTIVdSxqnrycxanVmUTb0xvECCJssuWEfSKjlB63g9kD8h8icd-cfAB8InWR8VnZJznP-7obtu-N__2h9mNuk5RZVc4noMT9fFuMbp4iYtTNlQHYlSlUB1eQy7HRDW__Q5cWUZjUFsQGRdgeKHb5YU-aKNI05xh9w42Pt7t57Ajcl8epKcHM2OH8JNHA_vTOX2YVSvGvMIhbJaPe5XAoPPV734fgLgnU2s
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3da9UwFA9zwvBF_LY6NYI-SVjTjyR9EBHnZXNu-LDBfatNk3ArW3u9bRH_Nf86z0nbO6-C-jIopZCEJie_c3KSnA9CXsjUJdLIjFntDEu0FCwTJmLG6iSxYexKhY7Cxyfi4Cz5ME_nW-TH5AuDZpWTTPSC2jQlnpHvIZBUqKQSe240i_i0P3uz_MowgxTetE7pNAaIHNnv32D71r4-3Ie5fhlFs_en7w7YmGGAaQBux7g1WSR1WgqNPqEatJ1EWCtCBZ2OZaYEV1bBICNY5YyLJDyysCZONXdhgRkjQPxfl3HKkcfkXF6uAoqrKVtfkgk52pbx2CeYWS1sf2GqFkDKU3jJGEP9XNMXXzbXxz-U3t9tN39ZDGe3yM1Ri6VvB9jdJlu2vkN2jsd7-rukOu21XZX9edNWLS1qQ72jF22WqO7jDTo0pJMhWN3CJ-0aV5RVV9WVZt783Ro6Rn1tKR4XUz-comsqQwHwCx-O6R45uxKS3yfbdVPbh4Qal4FyF2luSpMIrVRWhFyVzpnSgZbKA_IKCJovh7Adud_uxN4FeyJ_juTPB_IHREyEz8sxPjqm6Tj_d8Nw3fC__7U7zWw-yow2v0R4QJ6vi4Hb8QqnqG3TYx0F-pWEjXNAHgxAWP8zEiifVRoQuQGRdQWMJL5ZUlcLH1EcIxCFWfzo7916RnaA5fKPhydHj8kNGI4YbOZ2yXa36u0T0M46_dSzASWfr5rvfgKOQlB8
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Tuberculosis+and+other+opportunistic+infections+in+tofacitinib-treated+patients+with+rheumatoid+arthritis&rft.jtitle=Annals+of+the+rheumatic+diseases&rft.au=Winthrop%2C+K+L&rft.au=Park%2C+S-H&rft.au=Gul%2C+A&rft.au=Cardiel%2C+M+H&rft.series=Extended+report&rft.date=2016-06-01&rft.pub=BMJ+Publishing+Group&rft.issn=0003-4967&rft.eissn=1468-2060&rft.volume=75&rft.issue=6&rft.spage=1133&rft.epage=1138&rft_id=info:doi/10.1136%2Fannrheumdis-2015-207319&rft_id=info%3Apmid%2F26318385&rft.externalDocID=PMC4893093
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0003-4967&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0003-4967&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0003-4967&client=summon